Q-omics provides the consensus-scored ST8SIA6 profile across patient tissues and cancer cell-line models. ST8SIA6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ST8SIA6 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, ST8SIA6 RNA expression shows 16,899 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, LUAD, and THYM as cancer lineages where ST8SIA6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ST8SIA6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ST8SIA6 survival associations across molecular data types. ST8SIA6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ST8SIA6 RNA expression–survival associations across cancer types. High ST8SIA6 expression shows unfavorable associations in BLCA, STAD and MESO, but favorable associations in BRCA, LIHC and ESCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for ST8SIA6 RNA expression.
This table summarizes ST8SIA6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ST8SIA6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ST8SIA6 shows lower tumor expression in LUAD, KIRP, LUSC, BLCA, READ and COAD. The LUAD box plot shows higher ST8SIA6 RNA expression in normal versus tumor tissue (log2 FC = −2.706, t-test p < 0.001).
This table shows molecular features associated with ST8SIA6 in patient tissues and cancer cell lines. In patient samples, ST8SIA6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ST8SIA6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
